Drugs / Tertinat
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06590012 | Aug 2024 → Jul 2027 expected | coronary atherosclerosis | Institute for Atherosclerosis Research, Russia | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tertinat | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06590012 ↗ |
| Route | Oral | “Oral administration of Tertinat” NCT06590012 ↗ |